Aadi Bioscience, Inc. (AADI) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
17383 Sunset Boulevard
Pacific Palisades, CA 90272
United States of America (the)
Phone
424 473 8055
Website
Sector
Healthcare
Industry
Biotechnology
Employees
53
First IPO Date
February 16, 2018
| Name | Title | Pay | Year Born |
| David J. Lennon | President, Chief Executive Officer & Director | 654,400 | 1971 |
| Bryan Ball | Chief Technical Operations Officer | 460,173 | 1971 |
| Scott Giacobello | Chief Financial Officer, Treasurer, Investor Relations & Corporate Communications | 483,407 | 1970 |
| Neil Desai | Founder & Director | 1.66M | 1965 |
| Raymond G. Steitz | Senior Vice President of Human Resources & Chief Human Resources Officer | 0 | 1959 |
| Stephen Rodin | Senior Vice President of Legal & General Counsel | 0 | 1976 |
| David Dornan | Chief Scientific Officer | 0 | 1978 |
Aadi Bioscience, Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing highly targeted therapies for cancers defined by specific genetic alterations within the mTOR pathway. Its flagship drug candidate, FYARRO, is an investigational therapeutic composed of sirolimus conjugated with albumin. Aadi is actively evaluating FYARRO's efficacy in various malignancies that exhibit known mTOR pathway activation. This includes its application in 'tumor-agnostic' indications, where the focus is on specific genomic alterations that activate the mTOR pathway, irrespective of the tumor's origin. The company was established in 2007 and maintains its corporate headquarters in Pacific Palisades, California.